Meta description: This report covers a multicenter evaluation of an algorithm to predict delayed high grade conduction disturbances following transcatheter aortic valve replacement. The study uses retrospective health data collection across multiple centers and is sponsored by University Hospital Montpellier.
The study investigates a predictive model designed to forecast delayed high grade conduction disturbances after transcatheter aortic valve replacement. It is an observational study spread across several centers and relies on retrospective health data. The sponsor is University Hospital Montpellier and the project is active but not recruiting. Official registry details are available on ClinicalTrials.gov under NCT07414485.
What is the study about?
The multicenter observational study evaluates a predictive algorithm intended to forecast delayed conduction disturbances after transcatheter aortic valve replacement. The focus is on a real world setting where retrospective health data from several centers is used to test the model’s performance.
Intended purpose
The goal is to establish the algorithm’s usefulness for risk stratification after TAVR and to inform clinical and regulatory thinking about device based decision support tools.
Study population
Participants are drawn from multiple centers in a real world context, reflecting routine postprocedural care and follow up. No prospective enrollment is described in the source text, as the study uses retrospective data collection.
How is the study designed
The study is retrospective and observational and spans several centers. Data are sourced from existing health records rather than newly enrolled participants. The aim is to validate the predictive algorithm across diverse patient groups and device implementations in the TAVR setting.
Data sources
Health data from participating sites are used to train and test the algorithm without altering standard care. The approach reflects real world practice and supports regulatory exploration of algorithm based safety tools.
What outcomes are being evaluated and what does this mean for practice
The study seeks to assess how well the algorithm identifies patients who experience delayed conduction disturbances after transcatheter aortic valve replacement. Results will inform understanding of postprocedural monitoring needs and may shape considerations for device safety evaluation and labeling when predictive tools are involved.
Who is sponsoring and what is the status
University Hospital Montpellier serves as sponsor. The project is listed as active and not recruiting. The trial’s ClinicalTrials.gov page provides official registry information under NCT07414485. The existence of this trial supports ongoing attention to data driven tools in the TAVR pathway.
What are the regulatory implications
Findings from this multicenter validation may influence how predictive tools are viewed in device oversight and post market surveillance. Regulators will look for robust performance evidence, clear intended use statements, and appropriate data governance for algorithm based decision support in the TAVR setting.
- 1. What is being evaluated? The study evaluates the performance of a predictive algorithm to forecast delayed high grade conduction disturbances after TAVR using retrospective health data across multiple centers.
- 2. Who conducts this study? University Hospital Montpellier is the sponsor, and the study is multicenter and observational with retrospective data collection.
- 3. Where can official details be found? The study is active not recruiting and is registered on ClinicalTrials.gov under NCT07414485.
- 4. How could this affect patient care and regulation? If the algorithm proves useful, monitoring strategies after TAVR may be refined and regulatory discussions on device based predictive tools may be influenced.
Conclusion
In summary, the multicenter evaluation of the predictive algorithm addresses key questions about post TAVR risk. Regulators and clinicians should await published results to understand real world performance and implications for monitoring and safety. The work underscores the growing role of data driven tools in device oversight.
Disclaimer: This information is for professionals and is not legal advice. It does not replace regulatory guidelines or formal device submissions. Seek official resources for binding requirements.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07414485?term=medical+device